A Brazilian experience of the self transglutaminase-based test for celiac disease case finding and diet monitoring

Table 1 Demographic data of all the studied individuals¹

Group	Number	Female	Male	Median age	Range	Positivity
Healthy control	13	6	7	40.0	7-75	0
Celiac at diagnosis	6	4	2	41.2	28-61	5 (83.3%)1
GFD adherence	40	29	11	39.6	6-76	0
GFD transgression	6	4	2	24.0	10-38	6 (100.0%)1
First-degree relatives	79	56	23	30.7	5-79	3 (3.8%)1
Second-degree relatives	6	3	3	33.5	9-60	0
Dyspepsia	69	46	23	40.6	12-78	2 (2.9%)1
Irritable bowel syndrome	64	46	18	46.8	12-81	0
Crohn’s disease	8	5	3	35.6	27-45	0
Diarrhea	9	7	1	46.6	14-63	0
Total	300	206	94

¹In bold the number of individuals with a positive test and the respective percentages.

GFD: Gluten-free diet.

Table 2 Demographic data, correlation with antiendomysium antibodies, endoscopic and histological findings of duodenal biopsies for the positive individuals

	Age	Gender	IgA EmA	Biopsy	IEL	Endoscopy
Celiac at diagnosis
CPA	28	F	Positive	III-C	> 40	Scalloped folds, nodularity
CBO	38	F	Positive	III-C	40	Mosaic pattern
NHF	41	F	Positive	III-C	> 40	Nodularity, atrophic areas
AHR	42	M	Positive	III-C	45	Erosions, edema
HB	61	M	Negative	III-C	> 40	Decreased folds
GFD transgression
GSCS	10	M	Positive	III-C	55	Decreased folds, atrophic areas
ALM	19	F	Positive	III-A	NC	Atrophic areas
VC	23	F	Positive	III-C	> 40	Atrophic areas
FA	23	M	Positive	III-C	35	Decreased folds, atrophic areas
LGH	31	F	Positive	III-A	35	Decreased folds
RK	38	F	Positive	III-C	> 50	Atrophic areas
First-degree relatives
LGS	21	F	Positive	I	38	Normal
RG	48	F	Positive	III-C	48	Atrophy of folds
ERA	52	F	Negative	R	R	R
Dyspepsia
EJMS	21	F	Positive	III-A	50	Atrophy
LA	26	F	Positive	III-C	> 40	Scalloped folds, areas of atrophy

EmA: Antiendomysium; IEL: Percent of intraepithelial lymphocytes; NC: Not counted; R: Recommended.